Sikora Mariusz, Stec Albert, Chrabaszcz Magdalena, Giebultowicz Joanna, Samborowska Emilia, Jazwiec Radoslaw, Dadlez Michal, Olszewska Malgorzata, Rudnicka Lidia
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland.
J Inflamm Res. 2021 Jan 27;14:237-243. doi: 10.2147/JIR.S292544. eCollection 2021.
An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established.
To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier.
Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography.
One hundred and fourteen patients with psoriasis were finally enrolled in the study - 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05).
The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite - TMAO. Intestinal barrier modulation represents a new promising therapeutic approach.
越来越多的证据表明肠道通透性增加与慢性炎症性疾病的发病机制之间存在关联。然而,肠道屏障功能障碍在银屑病中的临床意义仍有待确定。
评估肠道屏障正常和改变的银屑病患者在疾病活动度、胃肠道症状严重程度和细菌代谢产物血浓度方面是否存在差异。
通过血清中claudin-3(一种肠道紧密连接调节剂)和肠脂肪酸结合蛋白(一种肠上皮细胞损伤标志物)的浓度评估肠道屏障完整性。使用经过验证的问卷评估胃肠道症状。采用高效液相色谱法测量肠道微生物群相关代谢产物氧化三甲胺(TMAO)的浓度。
最终114例银屑病患者纳入研究,其中68例肠道屏障改变,46例肠道屏障功能正常。肠道屏障改变的患者在胃肠道症状评分量表上的得分显著更高(3.20对1.46,p<0.001)。此外,肠道屏障受损的银屑病患者疾病活动度更高(银屑病面积和严重程度指数:19.7对10.3,p<0.001),全身炎症参数也更高(中性粒细胞与淋巴细胞比值:2.86对1.71,p<0.001;C反应蛋白3.76对1.92;p<0.05)。肠道完整性受损的银屑病患者细菌易位标志物显著更高(TMAO:375.7±51.9对119.4±27.5 ng/mL;p<0.05)。
银屑病患者肠道屏障改变与胃肠道症状、全身炎症特征以及肠道微生物群衍生代谢产物TMAO血浓度升高有关。肠道屏障调节是一种新的有前景的治疗方法。